Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Deciphera Pharmaceuticals, Inc. - Common Stock (NQ:DCPH)

25.59 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Deciphera Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Why Deciphera Pharmaceuticals Stock Jumped This Week ↗
The company's lead therapy received an FDA Breakthrough Therapy designation. 
Via The Motley Fool
News headline image
Stifel Is Bullish On This 'Competitive Late-Comer' In Gastric Cancer Space ↗
 
Via Benzinga
News headline image
Where Deciphera Pharmaceuticals Stands With Analysts ↗
 
Via Benzinga
News headline image
Top 5 Health Care Stocks That May Rocket Higher In Q1 2023 ↗
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
News headline image
Looking Into Deciphera Pharmaceuticals's Return On Capital Employed ↗
 
Via Benzinga
News headline image
Earnings Outlook For Deciphera Pharmaceuticals ↗
 
Via Benzinga
The Latest Analyst Ratings for Deciphera Pharmaceuticals ↗
 
Via Benzinga
Deciphera Pharmaceuticals's Return On Capital Employed Insights ↗
 
Via Benzinga
News headline image
Deciphera Earns Price Target Bump With Encouraging ESMO Presentation ↗
 
Via Benzinga
News headline image
$30M Bet On Deciphera Pharmaceuticals? Check Out These 4 Stocks Insiders Are Buying ↗
Although US stocks closed mixed on Tuesday, there were a few notable insider trades. 
Via Benzinga
News headline image
Why Jupiter Wellness Shares Are Trading Lower By Around 40%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Genius Group Limited (NYSE: GNS) jumped 87% to $1.00. Genius Group authorized issue of special dividend and appointed Timothy Murphy to lead Illegal Trading Task Force. 
Via Benzinga
News headline image
Dow Falls 200 Points; Jobless Claims Drop To 4-Month Low ↗
U.S. stocks traded lower this morning, with the Dow Jones dropping around 200 points on Thursday. 
Via Benzinga
News headline image
Why Deciphera Pharmaceuticals Stock Is Nosediving ↗
Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) shares are trading lower by 10.48% to $18.45 Thursday morning after the company announced a $125 million proposed public offering of common stock. 
Via Benzinga
News headline image
Why Starbox Group Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket ↗
Gainers Tricida, Inc. (NASDAQ: TCDA) rose 37.7% to $0.1898 in pre-market trading after gaining 4% on Wednesday. 
Via Benzinga
News headline image
Alcoa, H.B. Fuller And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
News headline image
Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Vivos Therapeutics, Inc. (NASDAQ: VVOS) shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023 ↗
 
Via Benzinga
News headline image
Alibaba, XPeng, Dada Nexus And Some Other Big Stocks Moving Higher On Wednesday ↗
U.S. stocks traded mixed, with the Dow Jones dropping around 20 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 4, 2023 ↗
 
Via Benzinga
News headline image
Deciphera's Stomach Cancer Treatment Shows Clinical Benefit In Subgroup Of Patients ↗
 
Via Benzinga
News headline image
Analyst Bullish On Theseus Pharma's Platform For Gastric Cancer Therapies ↗
 
Via Benzinga
News headline image
Deciphera Pharmaceuticals: Q3 Earnings Insights ↗
Deciphera Pharmaceuticals (NASDAQ:DCPH) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Earnings Outlook For Deciphera Pharmaceuticals ↗
Deciphera Pharmaceuticals (NASDAQ:DCPH) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
News headline image
Where Deciphera Pharmaceuticals Stands With Analysts ↗
Over the past 3 months, 7 analysts have published their opinion on Deciphera Pharmaceuticals (NASDAQ:DCPH) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
News headline image
McDonald's Price Target Cut By This Analyst, Plus Cowen Predicts $362 For Domino's Pizza ↗
Citigroup cut McDonald's Corporation (NYSE: MCD) price target from $275 to $246. McDonald's shares rose 0.5% to $245.00 in pre-market trading. 
Via Benzinga
News headline image
SVB Leerink Maintains Outperform Rating for Deciphera Pharmaceuticals: Here's What You Need To Know ↗
SVB Leerink has decided to maintain its Outperform rating of Deciphera Pharmaceuticals (NASDAQ:DCPH) and raise its price target from $21.00 to $25.00. Shares of Deciphera Pharmaceuticals are trading up... 
Via Benzinga
News headline image
This Analyst Slashes PT On Meta Platforms, Plus Mizuho Predicts $440 For Adobe ↗
Mizuho cut the price target for Adobe Inc (NASDAQ: ADBE) from $480 to $440. Adobe shares fell 1.3% to $389.82 in pre-market trading. 
Via Benzinga
News headline image
Bristol-Myers Squibb To $87? Here Are 5 Other Price Target Changes For Monday ↗
Atlantic Equities raised the price target on Bristol-Myers Squibb Company (NYSE: BMY) from $83 to $87. Atlantic Equities analyst Steve Chesney maintained an Overweight rating on the stock.... 
Via Benzinga
News headline image
4 Analysts Have This to Say About Deciphera Pharmaceuticals ↗
Within the last quarter, Deciphera Pharmaceuticals (NASDAQ:DCPH) has observed the following analyst ratings: 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 29, 2022 ↗
Upgrades 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.